Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1965 1
1967 1
1971 1
1972 1
1974 1
1975 6
1976 5
1977 9
1978 6
1979 12
1980 7
1981 9
1982 13
1983 19
1984 13
1985 27
1986 15
1987 17
1988 25
1989 25
1990 25
1991 46
1992 25
1993 28
1994 38
1995 45
1996 52
1997 54
1998 48
1999 55
2000 61
2001 71
2002 74
2003 88
2004 80
2005 88
2006 92
2007 126
2008 108
2009 123
2010 125
2011 114
2012 134
2013 166
2014 170
2015 149
2016 199
2017 232
2018 241
2019 235
2020 257
2021 281
2022 255
2023 200
2024 92

Text availability

Article attribute

Article type

Publication date

Search Results

3,965 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T. Simões EAF, et al. Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9. Lancet Child Adolesc Health. 2023. PMID: 36634694 Free PMC article.
BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at full term against medically attended RSV lower respiratory …
BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against r …
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data.
Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, Janssens W, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S Jr, Stelmach I, Kumar GT, Urashima M, Camargo CA Jr. Martineau AR, et al. BMJ. 2017 Feb 15;356:i6583. doi: 10.1136/bmj.i6583. BMJ. 2017. PMID: 28202713 Free PMC article. Review.
Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and to identify factors modifying this effect.Design Systematic review and meta-analysis of individual participant data (IPD) from randomised …
Objectives To assess the overall effect of vitamin D supplementation on risk of acute respiratory tract infection, and …
Bronchodilators for bronchiolitis.
Gadomski AM, Scribani MB. Gadomski AM, et al. Cochrane Database Syst Rev. 2014 Jun 17;2014(6):CD001266. doi: 10.1002/14651858.CD001266.pub4. Cochrane Database Syst Rev. 2014. PMID: 24937099 Free PMC article. Review.
BACKGROUND: Bronchiolitis is an acute, viral lower respiratory tract infection affecting infants and is sometimes treated with bronchodilators. ...DATA COLLECTION AND ANALYSIS: Two authors assessed trial quality and extracted data. We obtained unpublis …
BACKGROUND: Bronchiolitis is an acute, viral lower respiratory tract infection affecting infants and is sometimes treat …
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Gautret P, et al. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20. Int J Antimicrob Agents. 2020. PMID: 32205204 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive 600mg of hydroxychloroquine daily and their viral load in nasopharyngeal swabs was tested daily in a hospital setting. Depending on their …
PATIENTS AND METHODS: French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16(th), to receive …
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenthner S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Lebwohl MG, et al. N Engl J Med. 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629. N Engl J Med. 2021. PMID: 34879448 Clinical Trial.
A PGA response occurred in 35.4% of the patients in the tapinarof group and in 6.0% of those in the vehicle group in trial 1 and in 40.2% and 6.3%, respectively, in trial 2 (P<0.001 for both comparisons). ...Adverse events with tapinarof cream included folliculit …
A PGA response occurred in 35.4% of the patients in the tapinarof group and in 6.0% of those in the vehicle group in trial 1 and in 4 …
Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Gooderham MJ, et al. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28-S36. doi: 10.1016/j.jaad.2017.12.022. J Am Acad Dermatol. 2018. PMID: 29471919 Review.
Biomarker analyses show that dupilumab modulates the AD molecular signature and other Th2-associated biomarkers. Common adverse events reported in the clinical trials were nasopharyngitis, upper respiratory tract infection, injection site reactions, sk …
Biomarker analyses show that dupilumab modulates the AD molecular signature and other Th2-associated biomarkers. Common adverse events repor …
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M, Elewaut D, Ellis AM, Fleurinck C, Gaffney K, Gensler LS, Haroon N, Magrey M, Maksymowych WP, Marten A, Massow U, Oortgiesen M, Poddubnyy D, Rudwaleit M, Shepherd-Smith J, Tomita T, Van den Bosch F, Vaux T, Xu H. van der Heijde D, et al. Ann Rheum Dis. 2023 Apr;82(4):515-526. doi: 10.1136/ard-2022-223595. Epub 2023 Jan 17. Ann Rheum Dis. 2023. PMID: 36649967 Free PMC article.
METHODS: In parallel 52-week trials, patients with active disease were randomised 1:1 (nr-axSpA) or 2:1 (r-axSpA) to bimekizumab 160 mg every 4 weeks:placebo. ...Most frequent TEAEs with bimekizumab (>3%) included nasopharyngitis, upper respiratory tract …
METHODS: In parallel 52-week trials, patients with active disease were randomised 1:1 (nr-axSpA) or 2:1 (r-axSpA) to bimekizumab 160 …
High-dose methylprednisolone for acute traumatic spinal cord injury: A meta-analysis.
Liu Z, Yang Y, He L, Pang M, Luo C, Liu B, Rong L. Liu Z, et al. Neurology. 2019 Aug 27;93(9):e841-e850. doi: 10.1212/WNL.0000000000007998. Epub 2019 Jul 29. Neurology. 2019. PMID: 31358617
RESULTS: We enrolled 16 studies (1,863 participants) including 3 randomized controlled trials (RCTs) and 13 observational studies. Pooled results indicated that MP was not associated with an increase in motor score improvement (RCTs: p = 0.84; observational studies: p = 0. …
RESULTS: We enrolled 16 studies (1,863 participants) including 3 randomized controlled trials (RCTs) and 13 observational studies. Po …
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.
Napolitano M, D'Amico F, Ragaini E, Peyrin-Biroulet L, Danese S. Napolitano M, et al. Drug Des Devel Ther. 2022 Jun 17;16:1897-1913. doi: 10.2147/DDDT.S340459. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35747444 Free PMC article. Review.
Upadacitinib has been approved by the United States Food and Drug Administration for the induction and maintenance therapy of moderate-to-severe ulcerative colitis (UC) and is under investigation by the European Medicines Agency. Data from two induction and two maintenance Phase …
Upadacitinib has been approved by the United States Food and Drug Administration for the induction and maintenance therapy of moderate-to-se …
Evaluation of Daily Low-Dose Prednisolone During Upper Respiratory Tract Infection to Prevent Relapse in Children With Relapsing Steroid-Sensitive Nephrotic Syndrome: The PREDNOS 2 Randomized Clinical Trial.
Christian MT, Webb NJA, Mehta S, Woolley RL, Afentou N, Frew E, Brettell EA, Khan AR, Milford DV, Bockenhauer D, Saleem MA, Hall AS, Koziell A, Maxwell H, Hegde S, Prajapati H, Gilbert RD, Jones C, McKeever K, Cook W, Ives N. Christian MT, et al. JAMA Pediatr. 2022 Mar 1;176(3):236-243. doi: 10.1001/jamapediatrics.2021.5189. JAMA Pediatr. 2022. PMID: 34928294 Free PMC article. Clinical Trial.
OBJECTIVE: To investigate the use of daily low-dose prednisolone for the treatment of upper respiratory tract infection-related relapses. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial ( …
OBJECTIVE: To investigate the use of daily low-dose prednisolone for the treatment of upper respiratory tract infection …
3,965 results